Sarah Cohen, M.D.
Sarah Cohen, MD, is Vice President, Head of Clinical Development at Neogene Therapeutics. She is a physician-scientist experienced in drug development strategy from the pre-IND to first in human phase 1 and registrational phase 3 studies across multiple therapeutic areas (hematology, oncology, immune dysregulation, rare disease) with a passion for cell therapy. Before joining Neogene, […]
Heather Francis, M.S. Chem Eng.
Heather has held various leadership roles in the biopharmaceutical industry with responsibilities for development, validation, quality systems build and oversight, clinical and commercial operations and CMC product strategy within both established and start-up organizations including Amgen, Baxter, Boehringer Ingelheim, Kythera Biopharmaceuticals and Kite Pharma. Before joining Neogene in early 2021 as Head of Manufacturing & […]
Celeste Chang, M.S. Eng, MBA
Celeste has 20 years of experience in biopharmaceutical and cell therapy operations, manufacturing, and supply chain. Before joining Neogene in 2021 as Head of Supply Chain, she built and led various areas of Kite Pharma’s cell therapy commercial supply chain, including Planning, Product lifecycle management, and US Regional Supply Chain contributing to the successful commercial […]
Marianna Sabatino, M.D., Ph.D.
Dr. Sabatino has over 15 years of research experience in multiple scientific disciplines, with 13 years in the cell and gene therapy field. She has built and led Cell, Vector (Lenti and Retro) Process and Analytical Development teams and supported CMC strategy for early and late-stage lifecycle of multiple CAR-T and TCR-T assets including the […]
Sanjeeve Bala, M.D.
Sanjeeve Bala, MD, MPH, joined Neogene as Head, Regulatory Affairs, in September 2022. His industry career began at BeiGene USA, where he served as head of North America/Latin America Regulatory Affairs, developing strategy and overseeing multiple successful submissions to US FDA, HealthCanada, and other global health authorities. Prior to this, Sanjeeve was a Medical Officer […]
Sunny Xie
Sunny Xie is the Vice President of Biometrics at Neogene Therapeutics. Before joining Neogene, Sunny served as VP of Biometrics at OncoSec Medical, where he supported the development of strategy and execution of the immune oncology therapy pIL-12 with electroporation in combination with a checkpoint inhibitor. Before OncoSec, Sunny served as the VP of Biometrics […]
Sanne Weijzen, Ph.D.
Sanne Weijzen, Ph.D., is the Vice President, Head of Corporate Strategy and Global Operations at Neogene Therapeutics. Dr. Weijzen has more than 20 years of combined academic and biotech industry experience. Before joining Neogene, she spent 4 years as a COO of Scenic Biotech, where she was responsible for finance, HR, IP and legal, while […]
Marisa Leonard
Marisa is the Vice President, Chief of Staff to the CEO and Head of Business Development at Neogene Therapeutics. Prior to joining Neogene, Marisa spent nearly five years at Kite, a Gilead Company, where she worked in Business Development. Marisa worked on the Gilead / Kite acquisition and was responsible for leading cell therapy transactions […]
Harish Mundre
Harish Mundre is the Vice President, Head of Information Technology at Neogene Therapeutics. In over 20 active years in the tech industry, Mr. Mundre has held several senior roles in notable companies such as Sun Microsystems and Amgen Inc. Before Neogene, he served as a co-founder and CTO of Polar Wave Technologies where he helped […]
David Lund, Ph.D.
David Lund, Ph.D., is the Vice President, Intellectual Property at Neogene Therapeutics. Before coming to Neogene, Dr. Lund served most recently as Senior IP Counsel at Agenus, where his responsibilities included managing IP issues for Agenus’ affiliate AgenTus in addition to early stage and near-commercial antibody programs of Agenus. Prior to that, Dr. Lund was […]